Header Logo

Connection

Naoko Takebe to Antineoplastic Agents

This is a "connection" page, showing publications Naoko Takebe has written about Antineoplastic Agents.
Connection Strength

6.417
  1. Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials. Lancet. 2022 08 13; 400(10351):512-521.
    View in: PubMed
    Score: 0.535
  2. Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute. J Clin Oncol. 2022 06 10; 40(17):1949-1957.
    View in: PubMed
    Score: 0.519
  3. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. Nat Rev Clin Oncol. 2020 04; 17(4):204-232.
    View in: PubMed
    Score: 0.444
  4. Identification of high-risk drugs related to chemotherapy-induced peripheral neuropathy?in Cancer Therapy Evaluation Program-sponsored phase I trials. Eur J Cancer. 2019 07; 115:111-119.
    View in: PubMed
    Score: 0.428
  5. Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials. Cancer Sci. 2018 Jan; 109(1):207-214.
    View in: PubMed
    Score: 0.387
  6. Drug induced interstitial lung disease in oncology phase?I trials. Cancer Sci. 2016 Dec; 107(12):1830-1836.
    View in: PubMed
    Score: 0.360
  7. Sonic hedgehog signaling pathway and gallbladder cancer: targeting with precision medicine approach. Chin Clin Oncol. 2016 Feb; 5(1):1.
    View in: PubMed
    Score: 0.340
  8. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development. Jpn J Clin Oncol. 2015 Nov; 45(11):1001-6.
    View in: PubMed
    Score: 0.332
  9. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol. 2011 Feb; 8(2):97-106.
    View in: PubMed
    Score: 0.238
  10. Controversies in cancer stem cells: targeting embryonic signaling pathways. Clin Cancer Res. 2010 Jun 15; 16(12):3106-12.
    View in: PubMed
    Score: 0.230
  11. IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells. Mol Cancer Ther. 2006 Feb; 5(2):457-66.
    View in: PubMed
    Score: 0.170
  12. Combinatorial screen with apoptosis pathway targeted agents alrizomadlin, pelcitoclax, and dasminapant in multi-cell type tumor spheroids. SLAS Discov. 2025 Jun; 33:100230.
    View in: PubMed
    Score: 0.161
  13. Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts. Cancer Res Commun. 2024 03 19; 4(3):834-848.
    View in: PubMed
    Score: 0.149
  14. ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449. J Neurooncol. 2023 Jan; 161(1):33-43.
    View in: PubMed
    Score: 0.137
  15. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol. 2023 03 20; 41(9):1725-1734.
    View in: PubMed
    Score: 0.137
  16. Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. Cancer Cell. 2021 01 11; 39(1):38-53.e7.
    View in: PubMed
    Score: 0.119
  17. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. J Natl Cancer Inst. 2020 10 01; 112(10):1021-1029.
    View in: PubMed
    Score: 0.117
  18. A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines. Clin Pharmacol Ther. 2019 10; 106(4):803-809.
    View in: PubMed
    Score: 0.106
  19. Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells. PLoS One. 2018; 13(6):e0199361.
    View in: PubMed
    Score: 0.100
  20. Drug delivery of oral anti-cancer fluoropyrimidine agents. Expert Opin Drug Deliv. 2017 12; 14(12):1355-1366.
    View in: PubMed
    Score: 0.092
  21. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH. Curr Probl Cancer. 2017 May - Jun; 41(3):182-193.
    View in: PubMed
    Score: 0.091
  22. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016 Feb; 27(2):318-23.
    View in: PubMed
    Score: 0.084
  23. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. Cancer. 2016 Feb 15; 122(4):588-597.
    View in: PubMed
    Score: 0.084
  24. Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use. Clin Cancer Res. 2016 Feb 15; 22(4):1000-10.
    View in: PubMed
    Score: 0.083
  25. Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015 Jun; 21(6):1083-90.
    View in: PubMed
    Score: 0.080
  26. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. Am Soc Clin Oncol Educ Book. 2014; 71-6.
    View in: PubMed
    Score: 0.074
  27. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther. 2014 Feb; 141(2):140-9.
    View in: PubMed
    Score: 0.072
  28. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res. 2013 Nov 15; 19(22):6305-12.
    View in: PubMed
    Score: 0.072
  29. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67.
    View in: PubMed
    Score: 0.070
  30. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers. J Natl Cancer Inst. 2013 Jan 02; 105(1):11-24.
    View in: PubMed
    Score: 0.068
  31. International models of investigator-initiated trials: implications for Japan. Ann Oncol. 2012 Dec; 23(12):3151-3155.
    View in: PubMed
    Score: 0.067
  32. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Jun 08; 305(22):2327-34.
    View in: PubMed
    Score: 0.062
  33. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res. 2011 Feb 15; 17(4):654-66.
    View in: PubMed
    Score: 0.060
  34. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer. 2011 May 15; 117(10):2112-9.
    View in: PubMed
    Score: 0.059
  35. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010 Oct 20; 28(30):4609-15.
    View in: PubMed
    Score: 0.059
  36. A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples. Cancer Res Commun. 2024 09 01; 4(9):2384-2398.
    View in: PubMed
    Score: 0.039
  37. Acetalax (Oxyphenisatin Acetate, NSC 59687) and Bisacodyl Cause Oncosis in Triple-Negative Breast Cancer Cell Lines by Poisoning the Ion Exchange Membrane Protein TRPM4. Cancer Res Commun. 2024 08 01; 4(8):2101-2111.
    View in: PubMed
    Score: 0.038
  38. The Novel ATR Inhibitor M1774 Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer Drugs. Mol Cancer Ther. 2024 Jul 02; 23(7):911-923.
    View in: PubMed
    Score: 0.038
  39. The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers. Cancer Chemother Pharmacol. 2024 Aug; 94(2):157-167.
    View in: PubMed
    Score: 0.037
  40. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). J Clin Oncol. 2020 11 20; 38(33):3883-3894.
    View in: PubMed
    Score: 0.029
  41. Protection of bone marrow cells from toxicity of chemotherapeutic agents targeted toward thymidylate synthase by transfer of mutant forms of human thymidylate synthase cDNA. Prog Exp Tumor Res. 1999; 36:107-14.
    View in: PubMed
    Score: 0.026
  42. Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. Invest New Drugs. 2018 06; 36(3):442-450.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.